Champions Oncology, Inc. (CSBR) stock
CSBRNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends April 30
Financials through Q1 FY2027, quarter ended Jul 31, 2026Last filing: 10-Q on Sep 11, 2026Score 9/30251% above fair value
$4.65−0.13 (-2.72%)
Close on Nov 12, 2026Market cap $64.72MP/E –Yield –
Champions Oncology profit margin
Profit margin (net margin) is net income as a percentage of revenue.
Champions Oncology's profit margin for the twelve months ending Jul 31, 2026 was -1.8%. For fiscal 2026 it was -2.0%, against 8.3% the year before. The highest annual figure on record is 8.3% in fiscal 2025.
Annual profit margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2026 | Apr 30, 2026 | -2.0% | −10.2 |
| FY2025 | Apr 30, 2025 | 8.3% | +22.8 |
| FY2024 | Apr 30, 2024 | -14.5% | −4.6 |
| FY2023 | Apr 30, 2023 | -9.9% | −11.0 |
| FY2022 | Apr 30, 2022 | 1.1% | +0.2 |
| FY2021 | Apr 30, 2021 | 0.9% | +7.4 |
| FY2020 | Apr 30, 2020 | -6.5% | −10.9 |
| FY2019 | Apr 30, 2019 | 4.4% | +11.7 |
| FY2018 | Apr 30, 2018 | -7.3% | +37.4 |
| FY2017 | Apr 30, 2017 | -44.7% | +48.7 |
| FY2016 | Apr 30, 2016 | -93.4% | +54.8 |
| FY2015 | Apr 30, 2015 | -148.3% | −84.1 |
| FY2014 | Apr 30, 2014 | -64.1% | +11.9 |
| FY2013 | Apr 30, 2013 | -76.1% | +45.1 |
| FY2012 | Apr 30, 2012 | -121.1% | −65.9 |
| FY2011 | Apr 30, 2011 | -55.2% | – |
Quarterly profit margin
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q1 FY2027CQ2 2026 | Jul 31, 2026 | -2.8% | +0.5 |
| Q4 FY2026CQ1 2026 | Apr 30, 2026 | -4.8% | +10.0 |
| Q3 FY2026CQ4 2025 | Jan 31, 2026 | -1.7% | −28.1 |
| Q2 FY2026CQ3 2025 | Oct 31, 2025 | 1.8% | −3.6 |
| Q1 FY2026CQ2 2025 | Jul 31, 2025 | -3.3% | −12.7 |
| Q4 FY2025CQ1 2025 | Apr 30, 2025 | -14.9% | −14.1 |
| Q3 FY2025CQ4 2024 | Jan 31, 2025 | 26.4% | +47.4 |
| Q2 FY2025CQ3 2024 | Oct 31, 2024 | 5.4% | +23.3 |
| Q1 FY2025CQ2 2024 | Jul 31, 2024 | 9.3% | +29.8 |
| Q4 FY2024CQ1 2024 | Apr 30, 2024 | -0.8% | +18.8 |
| Q3 FY2024CQ4 2023 | Jan 31, 2024 | -21.1% | −2.0 |
| Q2 FY2024CQ3 2023 | Oct 31, 2023 | -17.9% | −17.8 |
| Q1 FY2024CQ2 2023 | Jul 31, 2023 | -20.4% | −18.1 |
| Q4 FY2023CQ1 2023 | Apr 30, 2023 | -19.6% | −16.9 |
| Q3 FY2023CQ4 2022 | Jan 31, 2023 | -19.1% | −25.1 |
| Q2 FY2023CQ3 2022 | Oct 31, 2022 | -0.1% | −2.5 |
| Q1 FY2023CQ2 2022 | Jul 31, 2022 | -2.3% | −0.8 |
| Q4 FY2022CQ1 2022 | Apr 30, 2022 | -2.7% | +3.7 |
| Q3 FY2022CQ4 2021 | Jan 31, 2022 | 6.0% | −2.9 |
| Q2 FY2022CQ3 2021 | Oct 31, 2021 | 2.4% | +2.3 |
| Q1 FY2022CQ2 2021 | Jul 31, 2021 | -1.5% | −2.3 |
| Q4 FY2021CQ1 2021 | Apr 30, 2021 | -6.4% | +18.4 |
| Q3 FY2021CQ4 2020 | Jan 31, 2021 | 8.9% | +8.0 |
| Q2 FY2021CQ3 2020 | Oct 31, 2020 | 0.0% | −4.0 |
| Q1 FY2021CQ2 2020 | Jul 31, 2020 | 0.8% | +10.3 |
| Q4 FY2020CQ1 2020 | Apr 30, 2020 | -24.7% | −21.5 |
| Q3 FY2020CQ4 2019 | Jan 31, 2020 | 0.8% | +6.6 |
| Q2 FY2020CQ3 2019 | Oct 31, 2019 | 4.0% | +0.0 |
| Q1 FY2020CQ2 2019 | Jul 31, 2019 | -9.5% | −17.3 |
| Q4 FY2019CQ1 2019 | Apr 30, 2019 | -3.3% | +9.6 |
| Q3 FY2019CQ4 2018 | Jan 31, 2019 | -5.7% | −4.2 |
| Q2 FY2019CQ3 2018 | Oct 31, 2018 | 4.0% | +5.8 |
| Q1 FY2019CQ2 2018 | Jul 31, 2018 | 7.8% | +21.2 |
| Q4 FY2018CQ1 2018 | Apr 30, 2018 | -12.8% | +52.3 |
| Q3 FY2018CQ4 2017 | Jan 31, 2018 | -1.5% | +38.0 |
| Q2 FY2018CQ3 2017 | Oct 31, 2017 | -1.8% | +9.5 |
| Q1 FY2018CQ2 2017 | Jul 31, 2017 | -13.4% | – |
| Q4 FY2017CQ1 2017 | Apr 30, 2017 | -65.2% | – |
| Q3 FY2017CQ4 2016 | Jan 31, 2017 | -39.5% | – |
| Q2 FY2017CQ3 2016 | Oct 31, 2016 | -11.3% | – |
See a number that looks wrong?